Risedronic acid
Based on 2 publication(s) in Google Scholar
Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.85%
- CAS No.: 105462-24-6
- Formule: C7H11NO7P2
- Masse moléculaire:283.11
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Risedronic acid
MoreVoir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 13762 | IC50 |
>40 μM
Compound: 1
|
Antiproliferative activity against rat 13762 cell line
Antiproliferative activity against rat 13762 cell line
|
[PMID: 16970405] |
| HepG2 | IC50 |
16 μM
Compound: Risedronate
|
Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR
Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR
|
[PMID: 20457823] |
| HFF | IC50 |
2.4 μM
Compound: 6
|
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
|
[PMID: 15857119] |
| JJN-3 | EC50 |
10 μM
Compound: 2
|
Antiproliferative activity against human JJN-3 after 72 hrs by MTT assay
Antiproliferative activity against human JJN-3 after 72 hrs by MTT assay
|
[PMID: 22390415] |
| KB | ED50 |
255 μM
Compound: 80
|
Dose to inhibit the growth of human KB carcinoma cell line
Dose to inhibit the growth of human KB carcinoma cell line
|
[PMID: 16162013] |
| MCF7 | IC50 |
248 μM
Compound: Risedronate
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay
|
[PMID: 33132173] |
| MCF7 | IC50 |
35.7 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cell line by MTT assay
Antiproliferative activity against human MCF7 cell line by MTT assay
|
[PMID: 16970405] |
| NCI-H460 | IC50 |
43.7 μM
Compound: 1
|
Antiproliferative activity against human NCI-H460 cell line by MTT assay
Antiproliferative activity against human NCI-H460 cell line by MTT assay
|
[PMID: 16970405] |
| RPMI-8226 | EC50 |
13 μM
Compound: 2a
|
Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay
Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay
|
[PMID: 23998921] |
| SF-268 | IC50 |
23.3 μM
Compound: 1
|
Antiproliferative activity against human SF-268 cell line by MTT assay
Antiproliferative activity against human SF-268 cell line by MTT assay
|
[PMID: 16970405] |
| T-cell | EC50 |
5 μM
Compound: 3
|
Effective concentration against human Gamma delta T cells
Effective concentration against human Gamma delta T cells
|
[PMID: 15828834] |
| T-cell | IC50 |
6.2 μM
Compound: 8
|
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
|
[PMID: 14711309] |
| T-cell | IC50 |
6.9 μM
Compound: 8
|
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
|
[PMID: 14711309] |
| Vero | ED50 |
55 μM
Compound: 5
|
Antimicrobial activity against Trypanosoma cruzi CL amastigotes infected in african green monkey Vero cells measured on day 3 by fluorescence assay
Antimicrobial activity against Trypanosoma cruzi CL amastigotes infected in african green monkey Vero cells measured on day 3 by fluorescence assay
|
[PMID: 24300918] |
| Vero | ED50 |
55 μM
Compound: Risedronate
|
Antiparasitic activity against Trypanosoma cruzi amastigotes infected in gamma-irradiated vero cells assessed as growth inhibition measured after 3 days by fluorescence assay
Antiparasitic activity against Trypanosoma cruzi amastigotes infected in gamma-irradiated vero cells assessed as growth inhibition measured after 3 days by fluorescence assay
|
[PMID: 23318904] |
| Vero | IC50 |
123 μM
Compound: 2
|
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
|
[PMID: 11300872] |
Risedronic acid (0-10 μM; 14 days) suppresses the formation of mineralized nodules in human mesenchymal stem cells (hMSC12) and rat thymus-derived mesenchymal stem cells (ST1BIIb)[1].
Risedronic acid (0-10 μM; 3 days) suppresses the mRNA expression of osteoblast marker gene osteocalcin (OC) in human mesenchymal stem cells (hMSC12)[1].
Risedronic acid (100-1000 μM; 48 h) induces chromatin condensation and activates caspase-3 in human mesenchymal stem cells (hMSC12)[1].
Risedronic acid (Risedronate) (15 μM; 36 h) inhibits isoprenoid biosynthesis in Plasmodium falciparum, as shown by the decreased intensities of bands corresponding to farnesol (FOH) and geranylgeraniol (GGOH)[3].
Risedronic acid (15 μM; 36 h) interferes with protein isoprenylation in Plasmodium falciparum, reducing the intensities of farnesylated protein bands and increasing those of geranylgeranylated protein bands[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human mesenchymal stem cells (hMSC12)
-
Concentration:100 μM, 300 μM, 500 μM, 1000 μM
-
Incubation Time:48 h
-
Result:Induced chromatin condensation and activated caspase-3.
Risedronic acid (10-25 mg/kg; intraperitoneal injection; once a day; 7 days) inhibits parasitemia in BALB/c mice infected with Plasmodium berghei strain ANKA, but does not prolong the survival time of mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57BL/6 mice (20-week-old, ~23 g) irradiated with 2 Gy X-rays whole-body2
-
Dosage:30 μg/kg
-
Administration:Subcutaneous injection, once every other day, for 3 weeks
-
Result:Prevented the radiation-induced increase in osteoclast number, surface, and TRAP5b.
-
Animal Model:Male BALB/c mice (3-4 weeks old) infected with Plasmodium berghei strain ANKA by intraperitoneal injection of 1×106 blood-stage parasites3
-
Dosage:10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg
-
Administration:Intraperitoneal injection, once a day, for 7 days
-
Result:Led to an 88.9% inhibition of the rodent parasite Plasmodium berghei in mice on the seventh day of treatment.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 105462-24-6
-
Appearance Solid
-
Masse moléculaire 283.11
-
Formule C7H11NO7P2
-
Color White to off-white
-
SMILES
OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=CC=C1
-
Synonyms
Risedronate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Respir Res
Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling. [Abstract]2022 Dec 28;23(1):380. PMID: 36575527 -
Int J Parasitol Drugs Drug Resist
Promising efficacy of nitrogen-containing bisphosphonates against the infection of Cryptosporidium spp. [Abstract]2025 Aug 6:29:100607. PMID: 40782657
Solvant et solubilité
0.1 M NaOH : 11 mg/mL (38.85 mM; ultrasonic and adjust pH to 7 with NaOH)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (313 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Fujita H, et al. Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells. Basic Clin Pharmacol Toxicol. 2011 Aug;109(2):78-84. [Content Brief]
[2]. Willey JS, et al. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations. Bone. 2010 Jan;46(1):101-11. [Content Brief]
[3]. Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| 0.1 M NaOH | 1 mM | 3.5322 mL | 17.6610 mL | 35.3220 mL | 88.3049 mL |
| 5 mM | 0.7064 mL | 3.5322 mL | 7.0644 mL | 17.6610 mL | |
| 10 mM | 0.3532 mL | 1.7661 mL | 3.5322 mL | 8.8305 mL | |
| 15 mM | 0.2355 mL | 1.1774 mL | 2.3548 mL | 5.8870 mL | |
| 20 mM | 0.1766 mL | 0.8830 mL | 1.7661 mL | 4.4152 mL | |
| 25 mM | 0.1413 mL | 0.7064 mL | 1.4129 mL | 3.5322 mL | |
| 30 mM | 0.1177 mL | 0.5887 mL | 1.1774 mL | 2.9435 mL |
Risedronic acid Related Classifications
HY-B0148 Related Classifications
Powered by Bioz